Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells
Open accessPublished version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Checkpoint kinase Chk1 is constitutively active in many cancer cell types and new generation Chk1 inhibitors show marked antitumor activity as single agents. Here we present a hitherto unrecognized mechanism that contributes to the response of cancer cells to Chk1-targeted therapy. Inhibiting chronic Chk1 activity in cancer cells induced the tumor suppressor activity of protein phosphatase protein phosphatase 2A (PP2A), which by dephosphorylating MYC serine 62, inhibited MYC activity and impaired cancer cell survival. Mechanistic investigations revealed that Chk1 inhibition activated PP2A by decreasing the transcription of cancerous inhibitor of PP2A (CIP2A), a chief inhibitor of PP2A activity. Inhibition of cancer cell clonogenicity by Chk1 inhibition could be rescued in vitro either by exogenous expression of CIP2A or by blocking the CIP2A-regulated PP2A complex. Chk1-mediated CIP2A regulation was extended in tumor models dependent on either Chk1 or CIP2A. The clinical relevance of CIP2A as a Chk1 effector protein was validated in several human cancer types, including neuroblastoma, where CIP2A was identified as an NMYC-independent prognostic factor. Because the Chk1–CIP2A–PP2A pathway is driven by DNA-PK activity, functioning regardless of p53 or ATM/ATR status, our results offer explanative power for understanding how Chk1 inhibitors mediate single-agent anticancer efficacy. Furthermore, they define CIP2A-PP2A status in cancer cells as a pharmacodynamic marker for their response to Chk1-targeted therapy. Cancer Res; 73(22); 6757–69. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625 · cited 10×
“Moreover, even though ATR kinase is a well-established upstream activator of Chk1 when DNA replication is impeded (14), or when cells are treated with DNA-damaging agents (14, 22), we do not understand the mechanisms driving chronic Chk1 activity in unperturbed human cancer cells.”
InfluentialRules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 6×
“Expression of the cancerous inhibitor of PP2A (CIP2A) has been proposed to be a potential mechanism for widespread inhibition of PP2A tumor suppressor activity in human malignancies (2, 4).”
InfluentialSelf-citationPP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295
Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012351108 · Cited by 249
Self-citationMYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185
Self-citationEfficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133 · cited 1×
“Notably, recent studies have shown that Chk1 activity is required for MYCinduced tumorigenesis (15, 16, 18).”
Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130
Self-citationCIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice
Ventelä, S., Côme, C., Mäkelä, J.-A., Hobbs, R. M., Mannermaa, L., Kallajoki, M., Chan, E. K., Pandolfi, P. P., Toppari, J., & Westermarck, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033209 · Cited by 58 · cited 1×
“Moreover, hypomorphic CIP2A mouse model (11) shows impaired MMTV-neu-driven mammary tumor development and progression (7).”
Self-citationMathiasen, D. P., Egebjerg, C., Andersen, S. H., Rafn, B., Puustinen, P., Khanna, A., Daugaard, M., Valo, E., Tuomela, S., Bøttzauw, T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.230 · Cited by 44
Self-citation
Research works printed but not linked: 27
- Sablina, 2008, SV40 small T antigen and PP2A phosphatase in cell transformation, Cancer Metastasis Rev, 27, 137, 10.1007/s10555-008-9116-0 · DOI
- Chen, 2010, CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells, Oncogene, 29, 6257, 10.1038/onc.2010.357 · DOI
- Guenebeaud, 2010, The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase, Mol Cell, 40, 863, 10.1016/j.molcel.2010.11.021 · DOI · Paper page
- Niemelä, 2012, CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes, Oncogene, 31, 4266, 10.1038/onc.2011.599 · DOI · Paper page
- Come, 2009, CIP2A is associated with human breast cancer aggressivity, Clin Cancer Res, 15, 5092, 10.1158/1078-0432.CCR-08-3283 · DOI · Paper page
- Basu, 2012, Targeting the DNA damage response in oncology: past, present and future perspectives, Curr Opin Oncol, 24, 316, 10.1097/CCO.0b013e32835280c6 · DOI
- Smith, 2010, The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer, Adv Cancer Res, 108, 73, 10.1016/B978-0-12-380888-2.00003-0 · DOI · Paper page
- Murga, 2011, Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors, Nat Struct Mol Biol, 18, 1331, 10.1038/nsmb.2189 · DOI · Paper page
- Tho, 2012, Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis, Oncogene, 31, 1366, 10.1038/onc.2011.326 · DOI
- Hoglund, 2011, Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells, Clin Cancer Res, 17, 7067, 10.1158/1078-0432.CCR-11-1198 · DOI
- Walton, 2012, CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs, Clin Cancer Res, 18, 5650, 10.1158/1078-0432.CCR-12-1322 · DOI
- Fishler, 2010, Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53, Oncogene, 29, 4007, 10.1038/onc.2010.163 · DOI · Paper page
- Lopez-Contreras, 2012, An extra alletle of Chk1 limits oncogene-induced replicative stress and promotes transformation, J Exp Med, 209, 455, 10.1084/jem.20112147 · DOI · Paper page
- Ma, 2011, Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics, Trends Mol Med, 17, 88, 10.1016/j.molmed.2010.10.009 · DOI · Paper page
- Partanen, 2007, Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization, Proc Natl Acad Sci U S A, 104, 14694, 10.1073/pnas.0704677104 · DOI · Paper page
- Geerts, 2010, The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification, Int J Cancer, 126, 2012, 10.1002/ijc.25074 · doi:10.1002/ijc.25074
- Shimada, 2008, Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression, Cell, 132, 221, 10.1016/j.cell.2007.12.013 · DOI · Paper page
- Blasius, 2011, A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1, Genome Biol, 12, R78, 10.1186/gb-2011-12-8-r78 · DOI · Paper page
- Khanna, 2011, ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells, PLoS One, 6, e17979, 10.1371/journal.pone.0017979 · DOI · Paper page
- Berthon, 1995, Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines, Int J Oncol, 6, 333
- Kim, 2008, Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo, PLoS One, 3, e1798, 10.1371/journal.pone.0001798 · DOI · Paper page
- Bretones, 2011, SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells, J Biol Chem, 286, 9815, 10.1074/jbc.M110.165977 · DOI
- Wilsker, 2008, Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control, Proc Natl Acad Sci U S A, 105, 20752, 10.1073/pnas.0806917106 · DOI · Paper page
- Li, 2005, Regulation of CHK2 by DNA-dependent protein kinase, J Biol Chem, 280, 12041, 10.1074/jbc.M412445200 · DOI · Paper page
- Lord, 2012, The DNA damage response and cancer therapy, Nature, 481, 287, 10.1038/nature10760 · DOI · Paper page
- Curtis, 2012, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, 486, 346, 10.1038/nature10983 · DOI · Paper page
- Virshup, 2009, From promiscuity to precision: protein phosphatases get a makeover, Mol Cell, 33, 537, 10.1016/j.molcel.2009.02.015 · DOI · Paper page
Cited by
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
Self-citationOncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95
Self-citationMeeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease
Shentu, Y.-P., Huo, Y., Feng, X.-L., Gilbert, J., Zhang, Q., Liuyang, Z.-Y., Wang, X.-L., Wang, G., Zhou, H., Wang, X.-C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.009 · Cited by 90
Self-citationClinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers
Khanna, A., & Pimanda, J. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.29431 · Cited by 57
Self-citation
Metadata
- Authors
- Khanna, A., Kauko, O., Böckelman, C., Laine, A., Schreck, I., Partanen, J. I., Szwajda, A., Bormann, S., Bilgen, T., Helenius, M., Pokharel, Y. R., Pimanda, J., Russel, M. R., Haglund, C., Cole, K. A., Klefström, J., Aittokallio, T., Weiss, C., Ristimäki, A., Visakorpi, T., & Westermarck, J.
- Venue
- Cancer Research
- Published
- 2013-11-14
- Volume
- 73
- Issue
- 22
- Pages
- 6757-6769
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2052113411
- Cited by
- 46
- References
- 10
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1002
- The paper
- Khanna, A., Kauko, O., Böckelman, C., Laine, A., Schreck, I., Partanen, J. I., Szwajda, A., Bormann, S., Bilgen, T., Helenius, M., Pokharel, Y. R., Pimanda, J., Russel, M. R., Haglund, C., Cole, K. A., Klefström, J., Aittokallio, T., Weiss, C., Ristimäki, A., . . . Westermarck, J. (2013). Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.